Equity research analysts tracking RxSight (RXST) maintain mixed projections and price targets reflecting recent commercial shifts and revised revenue forecasts. Consensus estimates provided by institutional financial platforms establish average twelve-month price targets hovering around eight to nine dollars per share, while algorithmic models present varying long-term trajectories based on market adoption rates of their light-adjustable technology. Because small-cap medical technology equities experience high volatility, investors should evaluate ongoing quarterly earnings, strategic partnerships, and professional broker assessments before trading.